Lv0
0 积分 2025-01-06 加入
Tislelizumab and hypofractionated radiotherapy plus nab-paclitaxel/gemcitabine as conversion therapy for BRPC/LAPC: A Phase II trial with dynamic biomarker monitoring
1个月前
已完结
Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma
3个月前
已完结
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial
5个月前
已完结
Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
6个月前
已完结
Adjuvant Chemoradiation and Immunotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Cancer
7个月前
已完结
KRAS Mutations as Predictive Biomarkers for First-Line Immune Checkpoint Inhibitor Monotherapy in Advanced NSCLC: A Systematic Review and Meta-Analysis
8个月前
已完结
皖公网安备34019202002308
